Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diagnosis and therapy are walking together on radiopeptides' avenue.

Literature DB >> 21365250

Diagnosis and therapy are walking together on radiopeptides' avenue.

Luigi Mansi, Irene Virgolini.

Abstract

Mesh：

Substances：

Year: 2011 PMID： 21365250 DOI： 10.1007/s00259-011-1762-8

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

36 in total

Review 1. Antibody vectors for imaging.

Authors: Tove Olafsen; Anna M Wu
Journal: Semin Nucl Med Date: 2010-05 Impact factor: 4.446

Review 2. Imaging of NETs with PET radiopharmaceuticals.

Authors: V Ambrosini; P Tomassetti; R Franchi; S Fanti
Journal: Q J Nucl Med Mol Imaging Date: 2010-02 Impact factor: 2.346

3. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors: Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal: J Clin Oncol Date: 2011-01-24 Impact factor: 44.544

4. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors: Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057

5. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.

Authors: Mary K G McStay; Dave Maudgil; Martin Williams; Jonathan M Tibballs; Anthony F Watkinson; Martyn E Caplin; John R Buscombe
Journal: Radiology Date: 2005-09-28 Impact factor: 11.105

6. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases.

Authors: Emilia S Olson; Tao Jiang; Todd A Aguilera; Quyen T Nguyen; Lesley G Ellies; Miriam Scadeng; Roger Y Tsien
Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205

7. 99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo.

Authors: Robert King; M Bashir-Uddin Surfraz; Ciara Finucane; Stefano C G Biagini; Philip J Blower; Stephen J Mather
Journal: J Nucl Med Date: 2009-03-16 Impact factor: 10.057

8. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.

Authors: Roland Haubner; Bertrand Kuhnast; Christian Mang; Wolfgang A Weber; Horst Kessler; Hans-Jürgen Wester; Markus Schwaiger
Journal: Bioconjug Chem Date: 2004 Jan-Feb Impact factor: 4.774

9. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544

10. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544

8 in total

1. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.

Authors: Vincenzo Cuccurullo; Luigi Mansi
Journal: Eur J Nucl Med Mol Imaging Date: 2012-05-30 Impact factor: 9.236

2. Decreased selenium levels after peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumours: implications for the antioxidant status.

Authors: Roy Moncayo; Annette Traeger
Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-21 Impact factor: 9.236

3. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

Authors: Agostino Chiaravalloti; Daniele Di Biagio; Mario Tavolozza; Ferdinando Calabria; Orazio Schillaci
Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-21 Impact factor: 9.236

4. Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.

Authors: Roland Haubner; David R Vera; Salman Farshchi-Heydari; Anna Helbok; Christine Rangger; Daniel Putzer; Irene J Virgolini
Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-12 Impact factor: 9.236

5. Microscale radiosynthesis, preclinical imaging and dosimetry study of [¹⁸F]AMBF₃-TATE: A potential PET tracer for clinical imaging of somatostatin receptors.

Authors: Ksenia Lisova; Maxim Sergeev; Susan Evans-Axelsson; Andreea D Stuparu; Seval Beykan; Jeffrey Collins; Jason Jones; Michael Lassmann; Ken Herrmann; David Perrin; Jason T Lee; Roger Slavik; R Michael van Dam
Journal: Nucl Med Biol Date: 2018-04-20 Impact factor: 2.408

6. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.

Authors: Roy Moncayo
Journal: EJNMMI Res Date: 2011-07-26 Impact factor: 3.138

7. [⁶⁸Ga]NOTA-Galactosyl Human Serum Albumin: a Tracer for Liver Function Imaging with Improved Stability.

Authors: Roland Haubner; Andreas M Schmid; Andreas Maurer; Christine Rangger; Llanos Geraldo Roig; Bernd J Pichler; Irene J Virgolini
Journal: Mol Imaging Biol Date: 2017-10 Impact factor: 3.488

8. Preclinical Evaluation of a Potential GSH Ester Based PET/SPECT Imaging Probe DT(GSHMe)₂ to Detect Gamma Glutamyl Transferase Over Expressing Tumors.

Authors: Harleen Khurana; Virendra Kumar Meena; Surbhi Prakash; Krishna Chuttani; Nidhi Chadha; Ambika Jaswal; Devinder Kumar Dhawan; Anil Kumar Mishra; Puja Panwar Hazari
Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240

8 in total